Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

O'Connell RJ, Excler JL, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Liu M, Wieczorek L, McNeil JG, El-Habib R, Michael NL, Gilliam BL, Paris R, VanCott TC, Tomaras GD, Birx DL, Robb ML, Kim JH.

J Infect Dis. 2016 Jun 15;213(12):1946-54. doi: 10.1093/infdis/jiw059. Epub 2016 Feb 11.

2.

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC.

Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9.

3.

Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Brown BK, Cox J, Gillis A, VanCott TC, Marovich M, Milazzo M, Antonille TS, Wieczorek L, McKee KT Jr, Metcalfe K, Mallory RM, Birx D, Polonis VR, Robb ML.

PLoS One. 2010 Nov 5;5(11):e13849. doi: 10.1371/journal.pone.0013849.

4.

Antigenic properties of peptide mimotopes of HIV-1-associated carbohydrate antigens.

Pashov A, Canziani G, Monzavi-Karbassi B, Kaveri SV, Macleod S, Saha R, Perry M, Vancott TC, Kieber-Emmons T.

J Biol Chem. 2005 Aug 12;280(32):28959-65. Epub 2005 Jun 14.

5.

Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.

Pashov A, MacLeod S, Saha R, Perry M, VanCott TC, Kieber-Emmons T.

Glycobiology. 2005 Oct;15(10):994-1001. Epub 2005 May 25.

PMID:
15917430
6.

Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Quinnan GV Jr, Yu XF, Lewis MG, Zhang PF, Sutter G, Silvera P, Dong M, Choudhary A, Sarkis PT, Bouma P, Zhang Z, Montefiori DC, Vancott TC, Broder CC.

J Virol. 2005 Mar;79(6):3358-69.

7.

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL.

J Virol. 2005 Jan;79(2):771-9.

8.
9.

Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein.

Rao M, Matyas GR, Vancott TC, Birx DL, Alving CR.

Immunol Cell Biol. 2004 Oct;82(5):523-30.

PMID:
15479438
10.

Macaque dendritic cells infected with SIV-recombinant canarypox ex vivo induce SIV-specific immune responses in vivo.

Villamide-Herrera L, Ignatius R, Eller MA, Wilkinson K, Griffin C, Mehlhop E, Jones J, Han SY, Lewis MG, Parrish S, Vancott TC, Lifson JD, Schlesinger S, Mascola JR, Pope M.

AIDS Res Hum Retroviruses. 2004 Aug;20(8):871-84.

PMID:
15320991
11.

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Mascola JR, Lewis MG, VanCott TC, Stiegler G, Katinger H, Seaman M, Beaudry K, Barouch DH, Korioth-Schmitz B, Krivulka G, Sambor A, Welcher B, Douek DC, Montefiori DC, Shiver JW, Poignard P, Burton DR, Letvin NL.

J Virol. 2003 Oct;77(19):10348-56.

12.

Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy.

O'Connell RJ, Merritt TM, Malia JA, VanCott TC, Dolan MJ, Zahwa H, Bradley WP, Branson BM, Michael NL, De Witt CC.

J Clin Microbiol. 2003 May;41(5):2153-5.

13.

Detection of mucosal antibodies in HIV type 1-infected individuals.

Wright PF, Kozlowski PA, Rybczyk GK, Goepfert P, Staats HF, VanCott TC, Trabattoni D, Sannella E, Mestecky J.

AIDS Res Hum Retroviruses. 2002 Nov 20;18(17):1291-300.

PMID:
12487817
14.

Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.

Farquhar C, VanCott TC, Mbori-Ngacha DA, Horani L, Bosire RK, Kreiss JK, Richardson BA, John-Stewart GC.

J Infect Dis. 2002 Oct 15;186(8):1173-6. Epub 2002 Sep 20.

15.

Human immunodeficiency virus (HIV)-specific antibody in cervicovaginal lavage specimens obtained from women infected with HIV type 1.

Williams SB, Flanigan TP, Cu-Uvin S, Mayer K, Williams P, Ettore CA, Artenstein AW, Duerr A, VanCott TC.

Clin Infect Dis. 2002 Sep 1;35(5):611-7. Epub 2002 Aug 7.

PMID:
12173138
16.

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.

Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, Tryniszewska E, Lewis MG, VanCott TC, Hirsch V, Woodward R, Gibson A, Grace M, Dobratz E, Markham PD, Hel Z, Nacsa J, Klein M, Tartaglia J, Franchini G.

J Virol. 2002 Jan;76(1):292-302.

17.

Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes.

Chen X, Scala G, Quinto I, Liu W, Chun TW, Justement JS, Cohen OJ, vanCott TC, Iwanicki M, Lewis MG, Greenhouse J, Barry T, Venzon D, Fauci AS.

Nat Med. 2001 Nov;7(11):1225-31.

PMID:
11689887
18.

Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.

Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, Michael NL, Jagodzinski L, Hawkes C, Mayers D, Gilliam BL, Birx DC, Robb ML.

AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1021-34.

PMID:
11485619
19.

HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.

Polonis VR, De Souza MS, Chanbancherd P, Chantakulkij S, Jugsudee A, Loomis-Price LD, Vancott TC, Garner R, Markowitz LE, Brown AE, Birx DL.

AIDS Res Hum Retroviruses. 2001 Jan 1;17(1):69-79.

PMID:
11177385
20.

Lack of association between human immunodeficiency virus type 1 antibody in cervicovaginal lavage fluid and plasma and perinatal transmission, in Thailand.

Chuachoowong R, Shaffer N, VanCott TC, Chaisilwattana P, Siriwasin W, Waranawat N, Vanprapar N, Young NL, Mastro TD, Lambert JS, Robb ML.

J Infect Dis. 2000 Jun;181(6):1957-63. Epub 2000 May 18.

PMID:
10837175
21.

Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.

Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB.

J Virol. 2000 Apr;74(7):3427-9.

22.

Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.

O'Hagan DT, Ugozzoli M, Barackman J, Singh M, Kazzaz J, Higgins K, Vancott TC, Ott G.

Vaccine. 2000 Mar 6;18(17):1793-801.

PMID:
10699327
23.

Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.

Gorny MK, VanCott TC, Williams C, Revesz K, Zolla-Pazner S.

Virology. 2000 Feb 15;267(2):220-8.

24.

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG.

Nat Med. 2000 Feb;6(2):207-10.

PMID:
10655111
25.

Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion.

Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, Barile A, VanCott TC, Vahey MT, McCutchan FE, Birx DL, Richman DD, Mascola JR.

Ann Intern Med. 1999 Oct 5;131(7):502-6.

PMID:
10507958
26.

Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.

VanCott TC, Mascola JR, Loomis-Price LD, Sinangil F, Zitomersky N, McNeil J, Robb ML, Birx DL, Barnett S.

J Virol. 1999 Jun;73(6):4640-50.

27.

Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Zolla-Pazner S, Gorny MK, Nyambi PN, VanCott TC, NĂ¡das A.

J Virol. 1999 May;73(5):4042-51.

28.

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL.

J Virol. 1999 May;73(5):4009-18.

29.

CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection.

Williams SB, Flanigan TP, Artenstein AW, VanCott TC, Smith D, Mayer K, Koup RA.

J Infect Dis. 1999 May;179(5):1310-2. No abstract available.

PMID:
10191415
30.

Application of dried blood spot specimens for serologic subtyping of human immunodeficiency virus type 1 in Thailand.

Chanbancherd P, Brown AE, Trichavaroj R, Tienamporn P, Puthakird P, Limpairojn N, VanCott TC, de Souza MS.

J Clin Microbiol. 1999 Mar;37(3):804-6.

31.

Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus.

Lewis MG, Yalley-Ogunro J, Greenhouse JJ, Brennan TP, Jiang JB, VanCott TC, Lu Y, Eddy GA, Birx DL.

J Virol. 1999 Feb;73(2):1262-70.

32.

Collection and processing of mucosal secretions from mice.

Kaminski RW, Vancott TC.

Methods Mol Med. 1999;17:329-39. doi: 10.1385/0-89603-369-4:329.

PMID:
21380685
33.

Collection and Processing of Mucosal Secretions from HIV-1 Infected Women.

Artenstein AW, Vancott TC.

Methods Mol Med. 1999;17:323-7. doi: 10.1385/0-89603-369-4:323.

PMID:
21380684
34.

Measurement of HIV-1 Specific and Total Antibody Secreting Cells by ELISPOT.

van Ginkel FW, Vancott JL, Kaminski R, Vancott TC.

Methods Mol Med. 1999;17:283-92. doi: 10.1385/0-89603-369-4:283.

PMID:
21380680
35.

Analysis of antibody-antigen interactions using surface plasmon resonance.

Vancott TC.

Methods Mol Med. 1999;17:273-82. doi: 10.1385/0-89603-369-4:273.

PMID:
21380679
36.

Analysis of Antibody Interactions with HIV-1 Envelope Expressed on the Surface of Acutely Infected H9 Cells.

Vancott TC, Hallberg PL.

Methods Mol Med. 1999;17:265-71. doi: 10.1385/0-89603-369-4:265.

PMID:
21380678
37.

HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992-1996.

Beyrer C, Vancott TC, Peng NK, Artenstein A, Duriasamy G, Nagaratnam M, Saw TL, Hegerich PA, Loomis-Price LD, Hallberg PL, Ettore CA, Nelson KE.

AIDS Res Hum Retroviruses. 1998 Dec 20;14(18):1687-91.

PMID:
9870323
38.

Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218).

Lambert JS, McNamara J, Katz SL, Fenton T, Kang M, VanCott TC, Livingston R, Hawkins E, Moye J Jr, Borkowsky W, Johnson D, Yogev R, Duliege AM, Francis D, Gershon A, Wara D, Martin N, Levin M, McSherry G, Smith G.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):451-61.

PMID:
9859958
39.

Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group.

Beyrer C, Artenstein AW, Rugpao S, Stephens H, VanCott TC, Robb ML, Rinkaew M, Birx DL, Khamboonruang C, Zimmerman PA, Nelson KE, Natpratan C.

J Infect Dis. 1999 Jan;179(1):59-67.

PMID:
9841823
40.

Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.

Frankel SS, Steinman RM, Michael NL, Kim SR, Bhardwaj N, Pope M, Louder MK, Ehrenberg PK, Parren PW, Burton DR, Katinger H, VanCott TC, Robb ML, Birx DL, Mascola JR.

J Virol. 1998 Dec;72(12):9788-94.

41.

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.

Stamatos NM, Mascola JR, Kalyanaraman VS, Louder MK, Frampton LM, Birx DL, VanCott TC.

J Virol. 1998 Dec;72(12):9656-67.

42.

Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection.

Loomis-Price LD, Cox JH, Mascola JR, VanCott TC, Michael NL, Fouts TR, Redfield RR, Robb ML, Wahren B, Sheppard HW, Birx DL.

J Infect Dis. 1998 Nov;178(5):1306-16.

PMID:
9780250
43.

Nationwide surveillance of HIV-1 prevalence and subtype in young Thai men.

Mason CJ, Kitsiripornchai S, Markowitz LE, Chanbancherd P, Supapongse T, Jugsudee A, Sirisopana N, Chuenchitra C, Torugsa K, VanCott TC, Michael RA, Nitayaphan S.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):165-73.

PMID:
9768626
44.

A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.

Gorny MK, Mascola JR, Israel ZR, VanCott TC, Williams C, Balfe P, Hioe C, Brodine S, Burda S, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 1998 Feb 10;14(3):213-21.

PMID:
9491911
45.

HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.

VanCott TC, Kaminski RW, Mascola JR, Kalyanaraman VS, Wassef NM, Alving CR, Ulrich JT, Lowell GH, Birx DL.

J Immunol. 1998 Feb 15;160(4):2000-12.

46.

Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

Gorny MK, VanCott TC, Hioe C, Israel ZR, Michael NL, Conley AJ, Williams C, Kessler JA 2nd, Chigurupati P, Burda S, Zolla-Pazner S.

J Immunol. 1997 Nov 15;159(10):5114-22.

PMID:
9366441
47.
48.

Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

VanCott TC, Mascola JR, Kaminski RW, Kalyanaraman V, Hallberg PL, Burnett PR, Ulrich JT, Rechtman DJ, Birx DL.

J Virol. 1997 Jun;71(6):4319-30.

49.

Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines.

Pincus SH, Messer KG, Cole R, Ireland R, VanCott TC, Pinter A, Schwartz DH, Graham BS, Gorse GJ.

J Immunol. 1997 Apr 1;158(7):3511-20.

PMID:
9120313
50.

Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG.

Lowell GH, Kaminski RW, VanCott TC, Slike B, Kersey K, Zawoznik E, Loomis-Price L, Smith G, Redfield RR, Amselem S, Birx DL.

J Infect Dis. 1997 Feb;175(2):292-301.

PMID:
9203649

Supplemental Content

Loading ...
Support Center